FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381377191> ?p ?o ?g. }

• W4381377191 abstract "ABSTRACT Introduction Recent clinical trials demonstrate that glucagon-like peptide-1 receptor agonists (GLP-1) elicit substantial reductions in glycemia and body weight in people with type 2 diabetes and obesity but must be continued indefinitely to maintain clinical improvements. Given the high cost and poor real-world persistence of GLP-1, an effective maintenance therapy that enables deprescription and sustained clinical improvements would be valuable. Thus, the purpose of this real-world study was to assess the effect of GLP-1 deprescription on glycemia and body weight following co-therapy with carbohydrate restricted nutrition therapy (CRNT) supported via telemedicine in a continuous remote care model among people with type 2 diabetes and excess body weight. Research Design and Methods A retrospective, propensity score matched cohort study among patients with type 2 diabetes at a nationwide telemedicine clinic was conducted using medical record data. Patients in whom GLP-1 were deprescribed (DeRx; n=154) were matched 1:1 with patients in whom GLP-1 were continued (Rx) or never prescribed (NonGLP). Longitudinal and between matched cohort differences in HbA1c and weight were assessed at enrollment, deprescription/index date, and 6 and 12 months (m) post-deprescription/index date using a linear mixed effects model. Results Hemoglobin A1c and body weight measured 6 and 12 months following deprescription/index date did not significantly differ between cohorts and improved at deprescription/index date and at follow up intervals compared to enrollment. HbA1c rose 6-and 12m post-deprescription/index in both DeRx and Rx and at 12m in NonGLP (p<0.001) but most patients maintained A1c<6.5%. No regression in body weight was observed with >70% maintaining ≥5% body weight loss 12m post-deprescription/index date. Conclusions These results demonstrate that CRNT in a continuous remote care model provides an effective GLP-1 step-off and maintenance therapy, allowing patients to discontinue GLP-1 while maintaining body weight loss and glycemia below therapeutic targets. KEY MESSAGES What is already known on this topic Glucagon-like peptide-1 receptor agonists (GLP-1) have demonstrated in clinical trials significant reductions in glycemia and body weight among patients with type 2 diabetes and obesity with rapid regression of clinical improvements upon discontinuation of the medication even with persistent caloric restriction and exercise counseling, suggesting the drug must be continued indefinitely. Cost and poor persistence of the GLP-1 therapy pose real-world challenges to maintaining improved health outcomes long-term, so therapies that enable deprescription and maintenance of clinical improvements are needed. What this study adds This study assessed the potential for utilization of carbohydrate restricted nutrition therapy (CRNT) supported via telemedicine in a continuous remote care model as a GLP-1 step-off and subsequent maintenance therapy. HbA1c and body weight up to 12 months following GLP-1 deprescription did not differ from matched cohorts in whom GLP-1 were continued or never utilized in this real-world study. How this study might affect research, practice or policy This study informs clinical practice, showing that the CRNT supported by continuous remote care provides an effective GLP-1 step-off therapy, enabling maintenance of improved glycemia and weight loss following GLP-1 deprescription and mitigating the need for lifetime, continuous use of the pharmaceutical." @default.
• W4381377191 created "2023-06-21" @default.
• W4381377191 creator A5005904700 @default.
• W4381377191 creator A5047799863 @default.
• W4381377191 date "2023-06-19" @default.
• W4381377191 modified "2023-09-24" @default.
• W4381377191 title "Effect of Glucagon-Like Peptide-1 Deprescription Following Nutrition Therapy via Telemedicine on Glycemia and Body Weight among People with Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study" @default.
• W4381377191 cites W1984845045 @default.
• W4381377191 cites W2162836078 @default.
• W4381377191 cites W2319839537 @default.
• W4381377191 cites W2769377885 @default.
• W4381377191 cites W2951175507 @default.
• W4381377191 cites W3106738979 @default.
• W4381377191 cites W3127371223 @default.
• W4381377191 cites W3132259365 @default.
• W4381377191 cites W3133746780 @default.
• W4381377191 cites W3134451425 @default.
• W4381377191 cites W3138431202 @default.
• W4381377191 cites W3152919084 @default.
• W4381377191 cites W3175572418 @default.
• W4381377191 cites W3177393241 @default.
• W4381377191 cites W4210809516 @default.
• W4381377191 cites W4221087049 @default.
• W4381377191 cites W4224218205 @default.
• W4381377191 cites W4281934192 @default.
• W4381377191 doi "https://doi.org/10.1101/2023.06.18.23291518" @default.
• W4381377191 hasPublicationYear "2023" @default.
• W4381377191 type Work @default.
• W4381377191 citedByCount "0" @default.
• W4381377191 crossrefType "posted-content" @default.
• W4381377191 hasAuthorship W4381377191A5005904700 @default.
• W4381377191 hasAuthorship W4381377191A5047799863 @default.
• W4381377191 hasBestOaLocation W43813771911 @default.
• W4381377191 hasConcept C126322002 @default.
• W4381377191 hasConcept C134018914 @default.
• W4381377191 hasConcept C167135981 @default.
• W4381377191 hasConcept C17923572 @default.
• W4381377191 hasConcept C201903717 @default.
• W4381377191 hasConcept C2777180221 @default.
• W4381377191 hasConcept C2780221984 @default.
• W4381377191 hasConcept C34320749 @default.
• W4381377191 hasConcept C511355011 @default.
• W4381377191 hasConcept C535046627 @default.
• W4381377191 hasConcept C544821477 @default.
• W4381377191 hasConcept C555293320 @default.
• W4381377191 hasConcept C71924100 @default.
• W4381377191 hasConcept C72563966 @default.
• W4381377191 hasConceptScore W4381377191C126322002 @default.
• W4381377191 hasConceptScore W4381377191C134018914 @default.
• W4381377191 hasConceptScore W4381377191C167135981 @default.
• W4381377191 hasConceptScore W4381377191C17923572 @default.
• W4381377191 hasConceptScore W4381377191C201903717 @default.
• W4381377191 hasConceptScore W4381377191C2777180221 @default.
• W4381377191 hasConceptScore W4381377191C2780221984 @default.
• W4381377191 hasConceptScore W4381377191C34320749 @default.
• W4381377191 hasConceptScore W4381377191C511355011 @default.
• W4381377191 hasConceptScore W4381377191C535046627 @default.
• W4381377191 hasConceptScore W4381377191C544821477 @default.
• W4381377191 hasConceptScore W4381377191C555293320 @default.
• W4381377191 hasConceptScore W4381377191C71924100 @default.
• W4381377191 hasConceptScore W4381377191C72563966 @default.
• W4381377191 hasLocation W43813771911 @default.
• W4381377191 hasOpenAccess W4381377191 @default.
• W4381377191 hasPrimaryLocation W43813771911 @default.
• W4381377191 hasRelatedWork W1482540465 @default.
• W4381377191 hasRelatedWork W2029784788 @default.
• W4381377191 hasRelatedWork W2102512961 @default.
• W4381377191 hasRelatedWork W2139452290 @default.
• W4381377191 hasRelatedWork W2350153196 @default.
• W4381377191 hasRelatedWork W3120244806 @default.
• W4381377191 hasRelatedWork W4205820411 @default.
• W4381377191 hasRelatedWork W4235834539 @default.
• W4381377191 hasRelatedWork W4280578915 @default.
• W4381377191 hasRelatedWork W1907997840 @default.
• W4381377191 isParatext "false" @default.
• W4381377191 isRetracted "false" @default.
• W4381377191 workType "article" @default.